Opus Genetics (NASDAQ:IRD) Now Covered by Analysts at Citizens Jmp

Key Points

• Citizens Jmp initiated coverage with a "market perform" rating and a $12 price target, implying roughly a 134% upside from the prior close.
• Analyst consensus is constructive: one Strong Buy, ten Buy, one Hold and one Sell, giving an average rating of "Moderate Buy" and an average target of $10.30.
• Clustered insider selling on April 23 (e.g., Ashwath Jayagopal sold 7,542 shares; CFO Robert Gagnon sold 7,842) — insiders have sold 73,395 shares in the past 90 days and own 11.7% — a concentrated sell-off likely pressured the stock.

Stock analysts at Citizens Jmp assumed coverage on shares of Opus Genetics (NASDAQ:IRD - Get Free Report) in a research note issued on Tuesday. The brokerage set a "market perform" rating and a $12.00 price target on the stock. Citizens Jmp's target price would indicate a potential upside of 134.38% from the company's previous close.

A number of other equities research analysts have also issued reports on the stock. Oppenheimer assumed coverage on shares of Opus Genetics in a report on Monday, March 16th. They set an "outperform" rating and a $10.00 target price for the company. Chardan Capital boosted their price target on shares of Opus Genetics from $9.00 to $11.00 and gave the company a "buy" rating in a research report on Thursday, March 12th. Lifesci Capital raised shares of Opus Genetics to a "strong-buy" rating in a research report on Thursday, February 12th. Craig Hallum set a $9.00 price target on shares of Opus Genetics and gave the company a "buy" rating in a research report on Wednesday, March 11th. Finally, Wedbush boosted their price target on shares of Opus Genetics from $8.00 to $10.00 and gave the company an "outperform" rating in a research report on Thursday, March 12th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $10.30.

Opus Genetics Stock Down 2.1%

Opus Genetics stock opened at $5.12 on Tuesday. Opus Genetics has a 52-week low of $0.81 and a 52-week high of $5.81. The firm has a market capitalization of $365.57 million, a price-to-earnings ratio of -6.24 and a beta of 0.52. The company has a fifty day simple moving average of $4.70 and a 200-day simple moving average of $3.09.

Insider Activity

In other news, insider Ashwath Jayagopal sold 7,542 shares of the business's stock in a transaction dated Thursday, April 23rd. The shares were sold at an average price of $5.19, for a total transaction of $39,142.98. Following the transaction, the insider owned 509,233 shares of the company's stock, valued at approximately $2,642,919.27. The trade was a 1.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Robert E. Gagnon sold 7,842 shares of the company's stock in a transaction dated Thursday, April 23rd. The shares were sold at an average price of $5.18, for a total transaction of $40,621.56. Following the completion of the transaction, the chief financial officer directly owned 592,158 shares in the company, valued at $3,067,378.44. The trade was a 1.31% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 73,395 shares of company stock worth $382,278. 11.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Occudo Quantitative Strategies LP acquired a new position in Opus Genetics in the fourth quarter valued at about $25,000. Comerica Bank acquired a new stake in shares of Opus Genetics during the first quarter worth about $29,000. Virtu Financial LLC acquired a new stake in shares of Opus Genetics during the fourth quarter worth about $34,000. Raymond James Financial Inc. lifted its position in shares of Opus Genetics by 95.6% during the third quarter. Raymond James Financial Inc. now owns 22,508 shares of the company's stock worth $37,000 after purchasing an additional 11,000 shares in the last quarter. Finally, Johnson Investment Counsel Inc. acquired a new stake in shares of Opus Genetics during the fourth quarter worth about $40,000. Institutional investors and hedge funds own 14.97% of the company's stock.

More Opus Genetics News

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Analyst interest remains constructive: recent coverage includes Oppenheimer initiating with an "Outperform" and Chardan raising its price target (and other firms issuing Buy/Strong-Buy views), which supports a higher medium-term valuation for IRD. Analyst coverage summary
• Neutral Sentiment: Opus announced management will participate in several leading ophthalmology and industry conferences in May 2026 — helps maintain investor/researcher visibility but is not an immediate clinical readout or revenue catalyst. Company conference participation
• Neutral Sentiment: Small institutional purchases and modest position changes were reported recently (new small stakes and a few increases by advisers); institutional ownership remains below major-cap levels, so flows may not strongly move the stock in either direction.
• Negative Sentiment: Clustered insider selling: several executives (CEO George Magrath, CFO Robert Gagnon, COO Joseph Schachle, President Benjamin Yerxa and others) disclosed sales on April 23rd totaling tens of thousands of shares at roughly $5.18–$5.24 per share. The company says these sales were to cover tax withholding on vested awards, but the concentrated timing likely exerted downward pressure on the share price today. Example filings: CEO form 4 and other SEC disclosures. CEO Form 4 InsiderTrades summary

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.